NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
B-cell Acute Lymphoblastic Leukemia
Large B-cell Lymphoma
Mantle Cell Lymphoma
Indolent Lymphoma
Waldenstrom Macroglobulinemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Aggressive Lymphoma
Large-cell Lymphoma

Interventions

BIOLOGICAL: NKX019

Sponsor

Nkarta, Inc.